无码国产精品一区二区,顾先生的金丝雀小说免费看,最新国产校花在线播放,中国黄色大片1,女人书小说迅雷下载迅雷下载迅雷下载迅雷下载地址,趴下老子要从后面cao你动漫,我的小婕子太紧了,亚洲超清无码制服丝袜无广告,亚洲线精品一区二区三区影音先锋

您好，歡迎來(lái)到上海士研管理咨詢(xún)有限公司
產(chǎn)業(yè)峰會(huì) 演講局 專(zhuān)家智庫(kù)服務(wù) 峰會(huì)活動(dòng)服務(wù) 整合營(yíng)銷(xiāo)服務(wù)
  • 產(chǎn)業(yè)峰會(huì)：
    以專(zhuān)業(yè)團(tuán)隊(duì)對(duì)產(chǎn)業(yè)和市場(chǎng)客觀詳實(shí)地調(diào)研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領(lǐng)導(dǎo)者關(guān)注的熱點(diǎn)話(huà)題與領(lǐng)袖代表，為您提供“一站式”的對(duì)話(huà)、分享、社交平臺(tái)!
  • 演講局：
    致力于為全球企業(yè)和機(jī)構(gòu)提供主題演講家、高管大師班、董事會(huì)顧問(wèn)，每項(xiàng)服務(wù)都提供了一種更深入、更具互動(dòng)性的體驗(yàn)，尤其是針對(duì)較小的精選受眾和關(guān)鍵個(gè)人。我們擁有最具影響力的商業(yè)領(lǐng)袖和頂級(jí)專(zhuān)家的資源，他們是各自領(lǐng)域的最杰出的代表。我們的團(tuán)隊(duì)由經(jīng)驗(yàn)豐富的演講和活動(dòng)經(jīng)理組成，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 專(zhuān)家智庫(kù)服務(wù)：
    中國(guó)領(lǐng)先的行業(yè)專(zhuān)家知識(shí)信息服務(wù)供應(yīng)商，為需要專(zhuān)業(yè)洞見(jiàn)的商業(yè)決策者匹配具有一手經(jīng)驗(yàn)的行業(yè)專(zhuān)家，助力他們以更加明確的目標(biāo)和堅(jiān)定的信心做出決策。我們有60萬(wàn)余名專(zhuān)家顧問(wèn)遍布二十多個(gè)行業(yè)，而且每天還在增加！
  • 峰會(huì)活動(dòng)服務(wù)：
    致力于成為全球最專(zhuān)業(yè)的產(chǎn)業(yè)峰會(huì)活動(dòng)提供商，為企業(yè)和機(jī)構(gòu)的產(chǎn)業(yè)性峰會(huì)活動(dòng)提供一站式專(zhuān)業(yè)服務(wù)，包括調(diào)研策劃、定制邀請(qǐng)、營(yíng)銷(xiāo)推廣、運(yùn)營(yíng)組織、項(xiàng)目管理、直播與數(shù)字化會(huì)議等，每項(xiàng)服務(wù)都由經(jīng)驗(yàn)豐富的專(zhuān)業(yè)團(tuán)隊(duì)匹配長(zhǎng)期沉淀的產(chǎn)業(yè)資源予以卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 整合營(yíng)銷(xiāo)服務(wù)：
    致力于成為全球領(lǐng)先的2B營(yíng)銷(xiāo)服務(wù)機(jī)構(gòu)，聚焦產(chǎn)業(yè)高端活動(dòng)、內(nèi)容、渠道的建設(shè)與沉淀，為客戶(hù)提供一站式整合營(yíng)銷(xiāo)解決方案，助力企業(yè)線(xiàn)上線(xiàn)下獲客與品牌筑造。我們深信專(zhuān)業(yè)團(tuán)隊(duì)匹配產(chǎn)業(yè)資源帶來(lái)卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
嘉賓信息
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 創(chuàng)始合伙人、創(chuàng)始人
所屬公司： 安龍基金、安龍生物
個(gè)人簡(jiǎn)介：
趙春林 博士，安龍基金創(chuàng)始合伙人，安龍生物創(chuàng)始人，為清華大學(xué)生物系首屆畢業(yè)生，獲得美國(guó)匹茲堡醫(yī)學(xué)院分子生物學(xué)博士和芝加哥大學(xué)工商管理碩士，曾任美國(guó)輝瑞制藥資深經(jīng)理，國(guó)科嘉和及康橋資本董事總經(jīng)理，擁有三十多年生命科學(xué)及醫(yī)療健康領(lǐng)域的創(chuàng)業(yè)和投資經(jīng)驗(yàn)，投資過(guò)信達(dá)生物，貝瑞合康，天鏡生物，歌禮藥業(yè)，萊凱醫(yī)藥，創(chuàng)響生物及國(guó)科恒泰等杰出企業(yè)。趙春林博士曾任清華大學(xué)生命科學(xué)院，醫(yī)學(xué)院及藥學(xué)院首屆校友會(huì)主席，為百華協(xié)會(huì)資深會(huì)員。 安龍基金是一只專(zhuān)注于國(guó)內(nèi)早期生命科學(xué)與醫(yī)療健康領(lǐng)域的基金，投資領(lǐng)域橫跨生命科學(xué)，醫(yī)藥研發(fā)，醫(yī)療器械，醫(yī)療服務(wù)及相關(guān)領(lǐng)域。 安龍生物是國(guó)內(nèi)核酸藥物領(lǐng)先企業(yè)，專(zhuān)注基因治療，RNA，基因編輯等核酸藥物的新藥研發(fā)。專(zhuān)業(yè)之外，趙春林博士喜歡足球，滑雪，曾做過(guò)DJ，擁有三個(gè)漂亮可愛(ài)的女兒。Chunlin Zhao, Ph.DFounder of the AnlongMed/AnlongBio. Dr. Zhao is among the first class graduated from Biological Science and Technology department at Tsinghua University in 1990. Then, he received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China, he founded Beijing LongMed biological technology co., LTD and then became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, GKHT and Imagine. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association of School of Life Sciences，School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading fund in Chinese life sciences and health care, focusing on biotech & pharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 聯(lián)合創(chuàng)始人/CTO
所屬公司： 北京啟辰生生物科技有限公司
個(gè)人簡(jiǎn)介：
曾任中國(guó)科學(xué)院北京基因組研究所研究生導(dǎo)師、2015年度國(guó)家十三五傳染病重大專(zhuān)項(xiàng)首席科學(xué)家；參加十一五重大藥物研發(fā)專(zhuān)項(xiàng)、承擔(dān)十二五、十三五 “重大新藥”創(chuàng)制項(xiàng)目；目前主持多項(xiàng)科技部和地方科委課題。國(guó)家和浙江、福建等省自然科學(xué)基金委評(píng)審專(zhuān)家；多個(gè)雜志編委；發(fā)表SCI論文 50余篇。Dr.Shi-you Li, Principle Investigator at Chinese Academy of Sciences Beijing Institute of Genomics prior to the founding of TRICISION BIO Ltd., Chief Scientist of the 13th Five-Year Plan National Major Project for Infectious Diseases in 2015, participated in the 11th Five-Year Plan Major Project for drug development and the 12th and 13th Five-Year Plan “Major New Drug” Development and Manufactor Project. Currently, Dr.Li presides over a number of projects of the Ministry of Science and Technology and local science and technology commissions, and is the peer review expert of the National and Zhejiang, Fujian and other provincial natural science foundations. Dr.Li has more than 50 scientific publication, and is on the editorial board for multiple journals.
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 董事長(zhǎng)兼CEO
所屬公司： 蘇州克睿基因生物科技有限公司
個(gè)人簡(jiǎn)介：
南京大學(xué)本科，清華大學(xué)博士，耶魯大學(xué)醫(yī)學(xué)院博士后、副研究員，歷任麥肯錫咨詢(xún)顧問(wèn)，上市公司生物藥發(fā)現(xiàn)&研發(fā)副總，現(xiàn)任蘇州克?；蛏锟萍加邢薰径麻L(zhǎng)。克?；?016年在蘇州成立，是一家專(zhuān)注于病毒遞送系統(tǒng)及基因編輯系統(tǒng)應(yīng)用開(kāi)發(fā)的創(chuàng)新基因細(xì)胞治療公司，致力于開(kāi)發(fā)腫瘤和遺傳疾病。公司成立以來(lái)完成近1億美元融資，并率先完成國(guó)內(nèi)首個(gè)病毒載體領(lǐng)域與全球Top20制藥公司的授權(quán)合作，建成了11000㎡的高規(guī)格基因編輯和基因治療研發(fā)生產(chǎn)中心。
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 創(chuàng)始人
所屬公司： 嘉晨西海生物技術(shù)有限公司
個(gè)人簡(jiǎn)介：
嘉晨西海生物技術(shù)有限公司創(chuàng)始人王子豪博士畢業(yè)于美國(guó)約翰霍普金斯大學(xué)，畢業(yè)后曾就職于多個(gè)國(guó)際大型制藥企業(yè)長(zhǎng)達(dá) 11 年之久，在職期間直接參與過(guò)四價(jià)流感、艾滋病、狂犬病、呼吸道合胞病毒、人巨細(xì)胞病毒等疫苗的 CMC 開(kāi)發(fā)。王子豪博士作為最早參與自復(fù)制 mRNA 工藝設(shè)計(jì)優(yōu)化和產(chǎn)業(yè)化開(kāi)發(fā)的人員之一，專(zhuān)注于 mRNA 技術(shù)平臺(tái)的工藝開(kāi)發(fā)8年，并且直接參與了 mRNA 技術(shù)平臺(tái)在多個(gè)病毒傳染病領(lǐng)域的有效性及安全性驗(yàn)證和臨床開(kāi)發(fā)等。Dr. Zihao Wang is the Chief Executive Officer at Immorna and Co-founder of the Immorna family of companies. Dr. Wang is a seasoned entrepreneur and established biopharmaceutical veteran. He has over 14 years of biotech R&D and leadership experience. He is one of the pioneers in self-replicating mRNA (srRNA) CMC development and is the mastermind behind the development of the mRNA platform technologies at Immorna, which include an improved next generation srRNA, conventional mRNA, and circular RNA. Dr. Wang pioneers the application of srRNA-LNP against oncology indications.Prior to founding the Immorna family of companies, Dr. Wang held various R&D roles at GSK Vaccines, Novartis Vaccines and Diagnostics, Grifols SA, etc. During his tenure at Novartis and GSK, he spent more than 7 years working directly on srRNA CMC development and the application of srRNA technology against various viral infectious diseases.Dr. Wang is the lead author on more than 20 publications with more than 2000 citations. He is also the inventor on multiple patents related to mRNA design, RNA delivery, and their applications in various disease areas. Dr. Wang received his B.S. in Biochemistry from Fudan University in Shanghai, and his Ph.D. in Biological Chemistry from The Johns Hopkins University.
微信公眾號(hào)
領(lǐng)導(dǎo)者網(wǎng)絡(luò)APP
Copyright ?2005 - 2017上海士研管理咨詢(xún)有限公司
犀牛云提供企業(yè)云服務(wù)